Third Quarter 2020 XPOVIO Net Product Sales of $21.3 Million; Quarterly Sales Continue Strong Momentum, Increasing Approximately 15% Compared to the Second Quarter of 2020 --
21,4 esperaban analistas según IB. -0,73 vs. -0,72 EPS esperado. Edito: según SA supera en ambas
Karyopharm Therapeutics EPS beats by $0.01, beats on revenue
«Después de nada, o después de todo/ supe que todo no era más que nada.»
#125135
Re: Farmas USA
Buenas noticias para $KPTI Karyopharm Announces Phase 3 SEAL Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Unresectable Dedifferentiated Liposarcoma
+23% AH
Karyopharm Therapeutics (NASDAQ:KPTI)announces positive results from a Phase 3 clinical trial, SEAL, evaluating Xpovio (selinexor) in patients with advanced unresectable dedifferentiated liposarcoma, a high-grade subtype of the rare form of soft tissue cancer that begins in fat cells.
The study met the primary endpoint of progression-free survival (PFS) with 30% less risk of cancer progression or death (hazard ratio = 0.70).
No new safety signals were observed.
Detailed results will be virtually presented at the Connective Tissue Oncology Society Annual Meeting on Friday, November 20.
The FDA approved Xpovio in July 2019 for multiple myeloma and in June of this year for diffuse large B-cell lymphoma.
